Amicus Therapeutics receives U.S. approval for Fabry disease drug

(OnNewsToday) – U.S. health regulators on Friday approved Amicus Therapeutics’ Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

Galafold, known chemically as migalastat, will be the first new Fabry treatment on the U.S. market in over 15 years, and will compete with Sanofi’s infused Fabrazyme.

Reporting by Robin Respaut; Editing by Phil Berlowitz

Our Standards:The Thomson OnNewsToday Trust Principles.

Related Posts

Add Comment